COVID-19 Vaccines

In December, the Centers for Disease Control and Prevention recommended prioritizing the Moderna and Pfizer shots over J&J’s because of its safety issues.

The meeting announcement follows months of frustration from families impatient for a chance to vaccinate their little children.

Moderna submitted data to the Food and Drug Administration that it hopes will prove two low-dose shots can protect babies, toddlers and preschoolers.

An arbitration panel in February decided that officers had to get vaccinated against COVID-19 or get a religious or medical exemption.

Some groups of people are eligible for second COVID-19 booster shots. But the advice around boosters can be confusing. Here’s what Penn experts suggest you know.

In a 2-1 ruling Thursday, a panel of the 5th Circuit Court of Appeals in New Orleans reversed a lower court and ordered dismissal of a lawsuit challenging the mandate.

Key questions include how often the vaccines should be updated against new viral strains and who should get them.

Health officials argue the protection of the COVID vaccine booster wanes over time and say some people need a second booster.

Testing sites have had to turn people away now that they can’t bill the federal government. Vaccinators are bracing for a similar fate.

Though findings are preliminary, many studies suggest that vaccinated people have good protection against the condition, although just how much is still up for debate.

Moderna said in the coming weeks it would ask regulators in the U.S. and Europe to authorize two small-dose shots for youngsters under 6.

In Pennsylvania, a growing number of divorced parents are taking their COVID vaccine disputes to court.

The request Thursday is broader than rival pharmaceutical company Pfizer’s request earlier this week for the regulator to approve a booster shot for all seniors.

Drugmaker Pfizer is expected to request authorization this week for an additional COVID-19 booster dose for seniors, according to a person familiar with the matter.

Penn researcher Drew Weissman spent decades developing mRNA technology. He says it helps target the rapidly mutating human immunodeficiency virus.